β1 selectivity of β-blockers and reduced risk of fractures in elderly hypertension patients

Bone

Volumn 51, Issue 6, 2012, Pages 1008-1015

  Song, Hong Ji ^a   Lee, Joongyub ^b   Kim, Ye Jee ^c   Jung, Sun Young ^d   Kim, Hwa Jung ^e   Choi, Nam Kyong ^b   Park, Byung Joo ^b,c,d  

^a Hallym University Sacred Heart Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Korea Institute of Drug Safety and Risk Management   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

Author keywords

blockers; Elderly; Fracture; Hypertension

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACEBUTOLOL; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMOSULALOL; ANGIOTENSIN ANTAGONIST; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BEVANTOLOL; BISOPROLOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CELIPROLOL; CLORANOLOL; CORTICOSTEROID; DIURETIC AGENT; METOPROLOL; NADOLOL; NIPRADILOL; PENBUTOLOL; PINDOLOL; PROPRANOLOL; PROTON PUMP INHIBITOR; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

AGED; ARTICLE; COHORT ANALYSIS; CONFOUNDING VARIABLE; CONTROLLED STUDY; DRUG SELECTIVITY; FEMALE; FOLLOW UP; HIP FRACTURE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK REDUCTION; SEX DIFFERENCE; SEX RATIO; SPINE FRACTURE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; FRACTURES, BONE; HUMANS; HYPERTENSION; MALE; RETROSPECTIVE STUDIES;

EID: 84867206100     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.08.126     Document Type: Article

References (56)

1. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303:2043-2050.
2. Lee H.S., Park Y.M., Kwon H.S., Lee J.H., Park Y.J., Lim S.Y., et al. Prevalence, awareness, treatment, and control of hypertension among people over 40years old in a rural area of South Korea: the Chungju Metabolic Disease Cohort (CMC) Study. Clin Exp Hypertens 2010, 32:166-178.
3. Choi K.M., Park H.S., Han J.H., Lee J.S., Lee J., Ryu O.H., et al. Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens 2006, 24:1515-1521.
4. Wada H., Hirano F., Kuroda T., Shiraki M. Breast arterial calcification and hypertension associated with vertebral fracture. Geriatr Gerontol Int 2012, 12:330-335.
5. Sennerby U., Melhus H., Gedeborg R., Byberg L., Garmo H., Ahlbom A., et al. Cardiovascular diseases and risk of hip fracture. JAMA 2009, 302:1666-1673.
6. Perez-Castrillon J.L., Martin-Escudero J.C., Alvarez Manzanares P., Cortes Sancho R., Iglesias Zamora S., Garcia Alonso M. Hypertension as a risk factor for hip fracture. Am J Hypertens 2005, 18:146-147.
7. Cappuccio F.P., Meilahn E., Zmuda J.M., Cauley J.A. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet 1999, 354:971-975.
8. Strandberg T.E. Cardiovascular disease, hypertension, and risk of hip fracture. JAMA 2010, 303:731. [author reply 731-2].
9. Sennerby U., Farahmand B., Ahlbom A., Ljunghall S., Michaelsson K. Cardiovascular diseases and future risk of hip fracture in women. Osteoporos Int 2007, 18:1355-1362.
10. Varosy P.D., Shlipak M.G., Vittinghoff E., Black D.M., Herrington D., Hulley S.B., et al. Fracture and the risk of coronary events in women with heart disease. Am J Med 2003, 115:196-202.
11. Solomon D.H., Mogun H., Garneau K., Fischer M.A. Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res 2011, 26:1561-1567.
12. Yang S., Nguyen N.D., Center J.R., Eisman J.A., Nguyen T.V. Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone 2011, 48:451-455.
13. Rejnmark L., Vestergaard P., Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006, 24:581-589.
14. Bonnet N., Gadois C., McCloskey E., Lemineur G., Lespessailles E., Courteix D., et al. Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 2007, 40:1209-1216.
15. Meisinger C., Heier M., Lang O., Doring A. Beta-blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg Cohort Study. Osteoporos Int 2007, 18:1189-1195.
16. Lim L.S., Fink H.A., Blackwell T., Taylor B.C., Ensrud K.E. Loop diuretic use and rates of hip bone loss and risk of falls and fractures in older women. J Am Geriatr Soc 2009, 57:855-862.
17. Lim L.S., Fink H.A., Kuskowski M.A., Taylor B.C., Schousboe J.T., Ensrud K.E. Osteoporotic Fractures in Men (MrOS) Study Group, Loop diuretic use and increased rates of hip bone loss in older men: the osteoporotic fractures in men study. Arch Intern Med 2008, 168:735-740.
18. Wasnich R., Davis J., Ross P., Vogel J. Effect of thiazide on rates of bone mineral loss: a longitudinal study. BMJ 1990, 301:1303-1305.
19. Rico H., Revilla M., Villa L.F., Arribas I., de Buergo M.A. A longitudinal study of total and regional bone mineral content and biochemical markers of bone resorption in patients with idiopathic hypercalciuria on thiazide treatment. Miner Electrolyte Metab 1993, 19:337-342.
20. Schlienger R.G., Kraenzlin M.E., Jick S.S., Meier C.R. Use of beta-blockers and risk of fractures. JAMA 2004, 292:1326-1332.
21. Pasco J.A., Henry M.J., Sanders K.M., Kotowicz M.A., Seeman E., Nicholson G.C. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis study. J Bone Miner Res 2004, 19:19-24.
22. Aung K., Htay T. Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev 2011, (10):CD005185.
23. Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO study group. Osteoporos Int 1994, 4:368-381.
24. Melton L.J., Chrischilles E.A., Cooper C., Lane A.W., Riggs B.L. Perspective. How many women have osteoporosis?. J Bone Miner Res 1992, 7:1005-1010.
25. Donaldson L.J., Cook A., Thomson R.G. Incidence of fractures in a geographically defined population. J Epidemiol Community Health 1990, 44:241-245.
26. Kannegaard P.N., van der Mark S., Eiken P., Abrahamsen B. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing 2010, 39:203-209.
27. Chang K.P., Center J.R., Nguyen T.V., Eisman J.A. Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 2004, 19:532-536.
28. Riggs B.L., Melton L.J. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995, 17:505S-511S.
29. Levasseur R., Sabatier J.P., Potrel-Burgot C., Lecoq B., Creveuil C., Marcelli C. Sympathetic nervous system as transmitter of mechanical loading in bone. Joint Bone Spine 2003, 70:515-519.
30. Elefteriou F., Ahn J.D., Takeda S., Starbuck M., Yang X., Liu X., et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005, 434:514-520.
31. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111:305-317.
32. Cherruau M., Facchinetti P., Baroukh B., Saffar J.L. Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone 1999, 25:545-551.
33. Turker S., Karatosun V., Gunal I. Beta-blockers increase bone mineral density. Clin Orthop Relat Res 2006, 443:73-74.
34. Wiens M., Etminan M., Gill S.S., Takkouche B. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med 2006, 260:350-362.
35. de Vries F., Souverein P.C., Cooper C., Leufkens H.G., van Staa T.P. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int 2007, 80:69-75.
36. Reid I.R., Gamble G.D., Grey A.B., Black D.M., Ensrud K.E., Browner W.S., et al. Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005, 20:613-618.
37. Reid I.R., Lucas J., Wattie D., Horne A., Bolland M., Gamble G.D., et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 2005, 90:5212-5216.
38. Rejnmark L., Vestergaard P., Kassem M., Christoffersen B.R., Kolthoff N., Brixen K., et al. Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 2004, 75:365-372.
39. Bonnet N., Pierroz D.D., Ferrari S.L. Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis. J Musculoskelet Neuronal Interact 2008, 8:94-104.
40. Kwon S. Payment system reform for health care providers in Korea. Health Policy Plan 2003, 18:84-92.
41. Choi H.J., Shin C.S., Ha Y.C., Jang S.M., Jang S.H., Park C.M., et al. Burden of osteoporosis in adults in Korea: a national health insurance database study. J Bone Miner Metab 2012, 30:54-58.
42. Park C., Ha Y.C., Jang S., Jang S., Yoon H.K., Lee Y.K. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab 2011, 29:744-751.
43. Lee Y.K., Jang S., Jang S., Lee H.J., Park C., Ha Y.C., et al. Mortality after vertebral fracture in Korea: analysis of the national claim registry. Osteoporos Int 2012, 237:1859-1865.
44. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42:1206-1252.
45. Levasseur R., Dargent-Molina P., Sabatier J.P., Marcelli C., Breart G. Beta-blocker use, bone mineral density, and fracture risk in older women: results from the Epidemiologie de L'osteoporose Prospective Study. J Am Geriatr Soc 2005, 53:550-552.
46. Bonnet N., Benhamou C.L., Malaval L., Goncalves C., Vico L., Eder V., et al. Low dose beta-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions. J Cell Physiol 2008, 217:819-827.
47. Togari A. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc Res Tech 2002, 58:77-84.
48. Altay H., Zorlu A., Binici S., Bilgi M., Yilmaz M.B., Colkesen Y., et al. Relation of serum parathyroid hormone level to severity of heart failure. Am J Cardiol 2012, 109:252-256.
49. Shane E., Mancini D., Aaronson K., Silverberg S.J., Seibel M.J., Addesso V., et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997, 103:197-207.
50. Germing A., Gotzmann M., Schikowski T., Vierkotter A., Ranft U., Kramer U., et al. High frequency of diastolic dysfunction in a population-based cohort of elderly women-but poor association with the symptom dyspnea. BMC Geriatr 2011, 11:71.
51. Zile M.R., Baicu C.F., Gaasch W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004, 350:1953-1959.
52. Alagiakrishnan K, Banach M, Jones LG, Datta S, Ahmed A, Aronow WS. Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. Ann Med in press, http://dx.doi.org/10.3109/07853890.2012.660493.
53. Masugata H., Senda S., Murao K., Inukai M., Hosomi N., Iwado Y., et al. Reduced bone mineral density in hypertensive patients is associated with left ventricular diastolic dysfunction, not left ventricular hypertrophy. Clin Exp Hypertens 2012, 34:176-181.
54. Xie F., Petitti D.B., Handler J. Changes in the continuation of antihypertensive drug use after ALLHAT. J Clin Hypertens (Greenwich) 2005, 7:649-653.
55. Wing L.M., Reid C.M., Ryan P., Beilin L.J., Brown M.A., Jennings G.L., et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348:583-592.
56. Caro J.J., Salas M., Speckman J.L., Raggio G., Jackson J.D. Persistence with treatment for hypertension in actual practice. CMAJ 1999, 160:31-37.